Lilly's VERVE-102 Shows Significant LDL-C Reduction in Phase 1b Trial
VERVE-102 reduced PCSK9 levels by up to 88% and LDL-C by up to 62% in Phase 1b trial, with effects lasting up to 18 months.
Therapeutic Area
Therapeutic area intelligence for Gene Editing with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.